Engineered Antibody Could Make a Breast Cancer Treatment Safer (1 of 3) (IMAGE)

American Association for the Advancement of Science (AAAS)

Engineered Antibody Could Make a Breast Cancer Treatment Safer (1 of 3)

Caption

The engineered bispecific antibody targets p95HER2 (blue fragment), which is unique to malignant breast cancer cells (brown). The antibody can therefore guide T cells (blue cells) to cancer cells without attacking healthy breast epithelial cells (pink). This material relates to a paper that appeared in the Oct. 3, 2018, issue of Science Translational Medicine, published by AAAS. The paper, by I. Rius Ruiz at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain, and colleagues was titled, "p95HER2-T cell bispecific antibody for breast cancer treatment."

Credit

Vall d'Hebron Institute of Oncology (VHIO)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.